IMIQUIMOD
| Brand name | ZYCLARA |
|---|---|
| Active ingredient | IMIQUIMOD |
| Strength | 3.75% |
| Dosage form | CREAM |
| Route | TOPICAL |
| Modality | Small molecule |
| FDA approval | March 2010 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10918635 | April 2030 | use U-1455 |
| 11202752 | April 2030 | use U-172 |
| 11850245 | April 2030 | use U-172 |
| 8236816 | December 2029 | use U-68 |
| 10238644 | December 2029 | use U-68 |
| 8299109 | December 2029 | use U-68 |
| 8598196 | August 2029 | use U-1455 |
| 10238645 | August 2029 | use U-1455 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.